| 1,083 | 3 | 137 |
| 下载次数 | 被引频次 | 阅读次数 |
利用CRISPR/Cas9基因编辑技术和同源重组技术在PD-L1基因的特定位置敲入绿色荧光蛋白(GFP)序列,构建含有PD-L1-GFP报告基因的结肠癌细胞(HT29)稳定细胞株。根据CRISPR-Cas9靶点设计原则,针对PD-L1基因终止密码子设计两对sgRNA,退火形成双链后连接至Lenti-V2空载质粒中,转化培养后提取质粒并测序验证。对于正确的Lenti-V2-sgRNA重组质粒,T7E1酶切验证其基因编辑效率。根据靶点位置设计左同源臂+GFP+右同源臂序列合成Donor片段,双酶切后连接至pUC19,重组载体转化扩增后同样进行质粒提取和测序验证。将验证成功的Lenti-V2-sgRNA和pUC19-donor-GFP共转染HT29细胞,荧光显微镜检测GFP表达情况,菌落PCR及基因测序验证GFP报告基因的靶向插入效果。经酶切和测序鉴定,靶向编辑PD-L1的Cas9载体Lenti-V2-gRNA和含GFP基因的Donor质粒pUC19-donor-GFP构建成功。两个重组质粒转染HT29细胞后,显微观察、多克隆验证、单克隆筛选及鉴定结果显示,GFP成功转入HT29细胞并进行了表达,经有限稀释法筛选出的单克隆细胞荧光均一,且与对照组相比,阳性细胞克隆的基因组PCR均检测到特异条带,表明在PD-L1终止密码子前成功插入了GFP片段,细胞株构建成功。通过基因编辑技术成功构建了稳定表达PD-L1-GFP报告基因的HT29结肠癌细胞株,建立了一个可以直观在细胞上观察PD-L1是否表达以及表达的强弱程度的系统,为后期体内外筛选调控PD-L1的上游新靶点及药物奠定了基础。
Abstract:Using CRISPR/Cas9 and homologous recombination technology to tap green fluorescent protein(GFP) sequence at specific position of PD-L1 gene, we constructed human colon cancer cell(HT29) stable cell line containing PD-L1-GFP reporter gene. According to the design principle of CRISPR-Cas9 target, two pairs of sgRNAs were designed for the stop codon of PD-L1 gene. After annealing, the sgRNAs were connected to the Lenti-V2 plasmid. The plasmid was extracted and verified by sequencing after amplification of the receptor cells. For the correct Lenti-V2-gRNA recombinant plasmid, the efficiency of gene editing was verified by T7E1 digestion. According to the target location, Donor fragment was synthesized from left homologous arm +GFP+ right homologous arm sequence, which was ligated to pUC19 after double enzyme digestion. Plasmid extraction and sequencing were also performed after recombinant vector transformation and amplification. HT29 cells were co-transfected with Lenti-V2-gRNA and pUC19-donor-GFP, and the expression of GFP protein was detected by fluorescence microscopy. Finally, the targeted insertion effect of GFP reporter gene was verified by colony PCR and gene sequencing. The Cas9 vector Lenti-V2-gRNA and Donor plasmid pUC19-donor-GFP containing PD-L1 were successfully constructed by enzyme digestion and sequencing. After the two recombinant plasmids were transfected into HT29 cells, the results of microscopic observation, polyclonal verification, monoclonal screening and identification showed that GFP was successfully transferred into HT29 cells and expressed, and the monoclonal cells screened by limited dilution method had uniform fluorescence. Moreover, compared with the control group, specific bands were detected in the genomic PCR of the clones of positive cells, indicating that the GFP fragment was successfully inserted before the PD-L1 stop codon, and the cell line was successfully constructed. HT29 colon cancer cell line with stable expression of PD-L1-GFP reporter gene was successfully constructed by gene editing technology, and a system was established to directly observe whether PD-L1 is expressed and the degree of expression, which laid a foundation for subsequent in vitro and in vivo screening of upstream new targets and drugs regulating PD-L1.
[1]谢丽叶,付杰军,卢奕,等.PD1/PD-L1激活促进癌症发生、发展和转移的研究进展[J].肿瘤防治研究,2017,44(6):423-427.
[2]车章洪.PD-1/PD-L1通路在肿瘤的发生发展过程中对T细胞的活化作用研究进展[J].中国新药杂志,2017,26(16):1913-1917.
[3]方宇,王海娟,李征洋,等.PD-L1和A2aR在大肠癌中的表达及意义[J].河北医药,2021,43(3):345-348,352.
[4]丰江舟,杨梦梦,朱彬彬,等.人PD-L1基因启动子克隆及其荧光素酶报告基因载体的构建[J].皖南医学院学报,2016,35(6):524-526.
[5]柯佳,李卓伟,李超,等.TGF-β1对结肠癌SW620细胞及其PD-L1表达的影响[C]//中国解剖学会.中国解剖学会2019年年会论文文摘汇编.昆明:解剖学杂志编辑部,2019:182.
[6]王秀超.胰腺癌肿瘤细胞PD-L1表达调控机制及联合干预实验研究[D].天津:天津医科大学,2017.
[7]李青丽,唐瑶,李富丽,等.抗PD-L1抗体抑制小鼠非小细胞肺癌移植瘤的生长及其机制[J].肿瘤,2020,40(8):531-540.
[8]孙晨,镡云辉,耿波,等.PD-1/PD-L1抑制剂在肾癌中的研究进展[J].国际外科学杂志,2020,47(9):639-643.
[9]张丽娜,杨艳芳,姜战胜.PD-1/PD-L1抑制剂治疗三阴性乳腺癌的研究进展[J].中国肿瘤生物治疗杂志,2021,28(8):844-849.
[10]李一鑫,路丹.PD-1/PD-L1抑制剂治疗晚期卵巢癌的研究进展[J].现代肿瘤医学,2021,29(15):2741-2744.
[11]陈茜,周建英,黎扬斯.抗PD-1/PD-L1治疗在晚期难治性肺鳞癌中的疗效和安全性[J].循证医学,2015,15(4):213-216.
[12]YUAN Y,ADAM A,ZHAO C,et al.Recent advancements in the mechanisms underlying resistance to PD-1/PD-L1 blockade immunotherapy[J].Cancers(BaseⅠ),2021,13(4):663.
[13]韩丽炘,黄玉,温娟娟.PD-1/PD-L1抑制剂联合化疗对比免疫单药治疗晚期NSCLC疗效及安全性的Meta分析[J].山西大同大学学报(自然科学版),2022,38(4):84-90.
[14]汝继轩,吴川林,张占田,等.PD-1/PD-L1免疫检查点抑制剂治疗胰腺癌研究进展[J].中华胰腺病杂志,2021,21(2):143-147.
[15]陈丽丽.EGFR联合PD-L1在可切除或临界可切除胰腺癌中的预后评价作用[C]//第二届中国临床分子诊断大会.第二届中国临床分子诊断大会论文集.成都:出版者不详,2019:73.
[16]YANG Z T,WANG Y,LIU S X,et al.Enhancing PD-L1 degradation by ITCH during MAPK inhibitor therapy suppresses acquired resistance[J].Cancer Discovery,2022,12(8):1942-1959.
基本信息:
DOI:10.13367/j.cnki.sdgc.2024.02.007
中图分类号:Q789
引用信息:
[1]谢钰珍,覃鸿妮,吴凡,等.基于CRISPR/Cas9基因编辑技术构建PD-L1-GFP报告基因HT29细胞株[J].山东理工大学学报(自然科学版),2024,38(02):67-72.DOI:10.13367/j.cnki.sdgc.2024.02.007.
基金信息:
江苏省高校“青蓝工程”项目(2023); 江苏省高职院校青年教师企业实践项目(2021QYSJ063); 江苏省精准诊疗药物创制工程研究中心(苏州大学)开放课题(SDGC2239)
2024-01-13
2024-01-13